TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inmune Bio ( (INMB) ) has issued an update.
On November 26, 2025, INmune Bio Inc. announced new employment agreements for key executives, effective November 1, 2025. David J. Moss, President and CEO, will receive a base salary of $500,000, a discretionary bonus, and stock options, with provisions for change of control and involuntary termination. Cory Ellspermann, CFO, will have a base salary of $275,000, a discretionary bonus, and stock options, with similar provisions. Mark Lowdell, Chief Scientific Officer, under the subsidiary INmune Bio International Limited, will receive a salary of £300,000, a discretionary bonus, and benefits, with terms for termination and severance. These agreements aim to secure leadership stability and align executive incentives with company performance.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. operates in the biotechnology industry, focusing on developing therapies that modulate components of the innate immune system to treat cancer and neurodegenerative diseases.
Average Trading Volume: 469,188
Technical Sentiment Signal: Sell
Current Market Cap: $43.87M
Learn more about INMB stock on TipRanks’ Stock Analysis page.